Ribomic (TSE:4591) Revenue: 円3.00 Mil (TTM As of Mar. 2026)


TSE:4591 Ribomic Inc TSE:4591
25 GF Score
Price 円74.00
! 3 Warning Signs
View Full Analysis

What is Ribomic Revenue?

Ribomic TSE:4591 -3.90% 25 Revenue is 円3.00 Mil as of Mar. 2026. GuruFocus rates TSE:4591 with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Ribomic's revenue for the six months ended in Mar. 2026 was 円3.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円3.00 Mil. Ribomic's Revenue per Share for the six months ended in Mar. 2026 was 円0.06. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.06.

Warning Sign:

Ribomic Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Ribomic was 15.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -69.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Ribomic's highest 3-Year average Revenue per Share Growth Rate was 73.30% per year. The lowest was -73.80% per year. And the median was -34.70% per year.


Ribomic  (TSE:4591) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Ribomic Revenue Related Terms


Ribomic Revenue Historical Data

* Premium members only.

The historical data trend for Ribomic's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ribomic Revenue Chart

Ribomic Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.91 65.97 0.00 2.11 3.00

Ribomic Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.11 0.00 0.00 3.00

TSE:4591 vs VRTX, REGN, ALNY: Revenue Comparison

For the Biotechnology subindustry, Ribomic's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ribomic Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ribomic's Revenue distribution charts can be found below:

* The bar in red indicates where Ribomic's Revenue falls into.


TSE:4591
25GF Score
Ribomic Inc TSE:4591
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ribomic Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円3.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of 円3.00 Mil mean?
Ribomic (TSE:4591) has a Revenue of 円3.00 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ribomic and its competitors.
Is Ribomic's Revenue too high?
Ribomic's current Revenue is 円3.00 Mil. Overall, Ribomic has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's Revenue compare to VRTX and REGN?
Ribomic's Revenue of 円3.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ribomic and its competitors. Ribomic's current Revenue is 円3.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current Revenue of 円3.00 Mil. The current Revenue is 円3.00 Mil. Ribomic's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Ribomic (TSE:4591), the current Revenue is 円3.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ribomic Business Description

Address 3-16-13 Usui Building, Shirokanedai, Minato-ku, Tokyo, JPN, 108-0071
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
25GF Score

Get the complete analysis for TSE:4591

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円74.00
Price